<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981834</url>
  </required_header>
  <id_info>
    <org_study_id>4P-21-1</org_study_id>
    <secondary_id>NCI-2021-05989</secondary_id>
    <secondary_id>4P-21-1</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT04981834</nct_id>
  </id_info>
  <brief_title>Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer</brief_title>
  <official_title>The Effect of Vesicopexy on Urinary Continence and Quality of Life Following Robotic-Assisted Radical Prostatectomy: A Phase III Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial compares the effects of robot-assisted radical prostatectomy (RARP) with&#xD;
      or without vesicopexy on urinary continence (a person's ability to control their bladder) and&#xD;
      quality of life in patients with cancer of the prostate. RARP is the most adopted surgical&#xD;
      approach for treatment of prostate cancer that has not spread to other places in the body&#xD;
      (non-metastatic). Urinary incontinence (inability to control the bladder) is one of the most&#xD;
      common complications of RARP, impacting patients' quality of life and psychological&#xD;
      well-being. Different techniques have been proposed to improve urinary continence following&#xD;
      RARP. Vesicopexy is one technique that restores the bladder to its normal position in the&#xD;
      body after RARP. This study aims to evaluate whether RARP with vesicopexy may improve urinary&#xD;
      continence and quality of life after surgery in prostate cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the 3-month (+/- 3 weeks) urinary continence following RARP with or without&#xD;
      vesicopexy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the 3-month (+/- 3 weeks) quality of life following RARP with or without&#xD;
      vesicopexy.&#xD;
&#xD;
      II. To evaluate the 24-hour post-operative (postop) urinary continence following RARP with or&#xD;
      without vesicopexy.&#xD;
&#xD;
      III. To evaluate the 1-month (+/- 1 week) postop urinary continence following RARP with or&#xD;
      without vesicopexy.&#xD;
&#xD;
      IV. To evaluate sexual function at 3-month (+/- 3 weeks) following RARP with or without&#xD;
      vesicopexy.&#xD;
&#xD;
      V. To evaluate the operative time in patients undergoing RARP with or without vesicopexy.&#xD;
&#xD;
      VI. To evaluate intraoperative complications in patients undergoing RARP with or without&#xD;
      vesicopexy.&#xD;
&#xD;
      VII. To evaluate 90-day post-operative complications in patients undergoing RARP with or&#xD;
      without vesicopexy.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients undergo standard RARP with anterior approach plus vesicopexy. Urethral&#xD;
      catheters are removed 7-14 days following surgery at provider discretion.&#xD;
&#xD;
      ARM II: Patients undergo standard RARP with anterior approach without vesicopexy. Urethral&#xD;
      catheters are removed 7-14 days following surgery at provider discretion.&#xD;
&#xD;
      After study completion, patients will be followed-up with at 24 hours, 1-month, and 3-months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-month (+/- 3 weeks) urinary continence rate following RARP with or without vesicopexy</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>Defined continence as 0-1 safety pad usage. Use the &quot;pictorial pad usage questionnaire.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-month (+/- 3 weeks) quality of life following surgery</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>Use the European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ-PR25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour postop urinary continence following surgery</measure>
    <time_frame>24 hours post-operative</time_frame>
    <description>Defined continence as 0-1 safety pad usage. Assessed with the &quot;pictorial pad usage questionnaire.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-month (+/- 1 week) post-operative urinary continence following surgery</measure>
    <time_frame>1 month post-operative</time_frame>
    <description>Defined continence as 0-1 safety pad usage. Assessed with the &quot;pictorial pad usage questionnaire.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function at 3-month (+/- 3 weeks) following surgery</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>Sexual Health Inventory for Men (SHIM) questionnaire is used for the evaluation of sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>Duration of operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative complications</measure>
    <time_frame>Duration of operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day post-operative complications</measure>
    <time_frame>90 days post-operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Stage I Prostate Cancer AJCC v8</condition>
  <condition>Stage II Prostate Cancer AJCC v8</condition>
  <condition>Stage IIA Prostate Cancer AJCC v8</condition>
  <condition>Stage IIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIC Prostate Cancer AJCC v8</condition>
  <condition>Stage III Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIA Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIC Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Arm I (radical prostatectomy, vesicopexy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo standard RARP with anterior approach plus vesicopexy. Urethral catheters are removed 7-14 days following surgery at provider discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (radical prostatectomy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo standard RARP with anterior approach without vesicopexy. Urethral catheters are removed 7-14 days following surgery at provider discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (radical prostatectomy, vesicopexy)</arm_group_label>
    <arm_group_label>Arm II (radical prostatectomy)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (radical prostatectomy, vesicopexy)</arm_group_label>
    <arm_group_label>Arm II (radical prostatectomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Prostatectomy</intervention_name>
    <description>Undergo RARP</description>
    <arm_group_label>Arm I (radical prostatectomy, vesicopexy)</arm_group_label>
    <arm_group_label>Arm II (radical prostatectomy)</arm_group_label>
    <other_name>Prostatovesiculectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vesicopexy</intervention_name>
    <description>Undergo vesicopexy</description>
    <arm_group_label>Arm I (radical prostatectomy, vesicopexy)</arm_group_label>
    <other_name>Cystopexy</other_name>
    <other_name>Vesicofixation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men with age &gt; 18 years&#xD;
&#xD;
          -  Prostate cancer patients undergoing RARP with anterior approach at University of&#xD;
             Southern California (USC) urology&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent&#xD;
&#xD;
          -  Clinical stage &lt; 4 and (M0) prostate cancer&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score 0-1&#xD;
&#xD;
          -  Pre-operative (op) urinary continence&#xD;
&#xD;
          -  Negative history of pelvic radiation and/or previous local therapy for prostate cancer&#xD;
             (i.e., radiation or focal therapy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of psychiatric, neurologic or cognitive disease&#xD;
&#xD;
          -  Any history of neuropathic bladder&#xD;
&#xD;
          -  Any drug or alcohol addiction&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hooman Djaladat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ileana Aldana</last_name>
    <phone>323-865-0702</phone>
    <email>Ileana.aldana@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hooman Djaladat</last_name>
      <phone>323-865-3700</phone>
      <email>Djaladat@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Hooman Djaladat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

